Subscribe
dna-istock-518143098-ralwel-
Ralwel / iStockphoto.com
17 April 2019Americas

US university treats cancer patients with CRISPR

The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.

More on this story

Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB